cell engineering

[Annual Review of Biomedical Engineering] Investigators examine the body of literature that encompasses microfluidic applications where human iPSCs are derived starting from human somatic cells and where human pluripotent stem cells are differentiated into different cell types.

[Nature Biotechnology] The authors described an implantable Multifunctional Alginate Scaffold for T Cell Engineering and Release that streamlined in vivo CAR-T cell manufacturing and reduced processing time to a single day.

[Intellia Therapeutics, Inc.] Intellia Therapeutics, Inc. announced that the first patient has been dosed with NTLA-5001, the company’s ex vivo CRISPR/Cas9 genome editing candidate for the treatment of AML.

[Applied Materials Today] Scientists showed that MSCs cultured in hPL displayed a reduced cell size and cell spreading, but an improved proliferation and osteogenic capability compared with cells maintained in fetal bovine serum.

[Trends in Cancer] The authors synthesize recent findings on T cell antigen receptor and CAR signaling and highlights the potential strategies of T cell engineering by signaling refinement.

[Shoreline Biosciences] Dendreon Pharmaceuticals and Shoreline Biosciences, a biotechnology company developing allogeneic off-the-shelf, standardized, and targeted natural killer and macrophage cellular immunotherapies derived from iPSC for cancer, announced an alliance to advance the future of iPSC-derived cellular therapies.